Gufic Biosciences Limited

Gufic Biosciences Announces Special Window for Physical Share Transfer

Gufic Biosciences announces a special window for re-lodgement of physical share transfer requests from July 7, 2025, to January 6, 2026, as per SEBI guidelines.

Gufic Biosciences Announces Upload of Earnings Conference Call Transcript

Gufic Biosciences Limited uploaded the written transcript of its earnings conference call held on November 17, 2025, which is now accessible on the company's website.

Gufic Biosciences to meet analysts/institutional investors on November 21, 2025

Gufic Biosciences will hold an analyst/institutional investor meeting on November 21, 2025, at JM Financial India Xchange 2025 in Mumbai to discuss published information.

Audio Recording of Earnings Conference Call Uploaded

Gufic Biosciences Limited has uploaded the audio recording of its earnings conference call held on November 17, 2025, on the company's website. The written transcript will be submitted later.

Gufic Biosciences Announces Unaudited Financial Results for Quarter Ended 30 Sep 2025

Gufic Biosciences announced unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. The results were approved by the board on November 14, 2025.

Gufic Biosciences Announces Investor Presentation for Q2FY26

Gufic Biosciences Limited has released an investor presentation regarding the unaudited financial results for the quarter and half year ended September 30, 2025.

Gufic Biosciences Approves Unaudited Financial Results for Quarter Ended Sep 30, 2025

Gufic Biosciences board approves unaudited results for quarter ended September 30, 2025. Standalone net profit: ₹1,493.71 Lakh. Consolidated net profit: ₹1,682.40 Lakh. Investment in Gufic Ireland Limited made on August 25, 2025.

Gufic Biosciences to host Earnings Conference Call on November 17, 2025

Gufic Biosciences will host an Earnings Conference Call on November 17, 2025, at 4:30 p.m. IST, for investors and analysts to discuss business, prospects, and financial performance.

ICRA reaffirms Gufic Biosciences' credit ratings for enhanced bank facilities

ICRA reaffirmed Gufic Biosciences' long-term A-(Stable) and short-term A2+ credit ratings for enhanced bank facilities totaling ₹150 crore, up from ₹50 crore.

Gufic Biosciences Launches 'Saksham Niveshak' Campaign for Unclaimed Dividends

Gufic Biosciences launched the 'Saksham Niveshak' campaign from July 28 to November 06, 2025, to help shareholders claim unpaid dividends and update KYC details, as requested by IEPFA.

Certificate under SEBI Regulations for Quarter Ended September 30, 2025

Gufic Biosciences Limited submits a certificate under SEBI Regulations for the quarter ended September 30, 2025, confirming the dematerialization of securities.

Gufic Biosciences Concludes 41st AGM; Approves Dividend & Director Appointments

Gufic Biosciences Announces Special Window for Physical Share Re-lodgement

Gufic Biosciences to meet with DAM Capital's Pharma & Healthcare Conference

Gufic Biosciences promotes Shekhar Aley to President – Critical Care SBUs, Nepal & Institution

Gufic Biosciences to convene 41st AGM on Sep 29, 2025, proposes 10% dividend for FY25

Gufic Biosciences invests in Gufic Ireland Limited

Gufic Biosciences Uploads Transcript of Earnings Conference Call

Gufic Biosciences Announces Special Window for Physical Share Transfer